Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Etienne Giroux Leprieur,1,2 Vincent Fallet,3,4 Jacques Cadranel,3,4 Marie Wislez3,4 1Respiratory Diseases and Thoracic Oncology Department, APHP-Ambroise Paré Hospital, Boulogne-Billancourt, France; 2EA4340 Laboratory, UVSQ, Paris-Saclay University, France; 3Respiratory Diseases Departmen...

Full description

Bibliographic Details
Main Authors: Giroux Leprieur E, Fallet V, Cadranel J, Wislez M
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:Lung Cancer : Targets and Therapy
Subjects:
ALK rearrangement
crizotinib
non-small cell lung carcinoma
Online Access:https://www.dovepress.com/spotlight-on-crizotinib-in-the-first-line-treatment-of-alk-positive-ad-peer-reviewed-article-LCTT

Internet

https://www.dovepress.com/spotlight-on-crizotinib-in-the-first-line-treatment-of-alk-positive-ad-peer-reviewed-article-LCTT

Similar Items